This study is a randomised double blind, parallel group, and will evaluate the effects of
repeat oral doses of RSG- XR for 21 days on the QTc interval compared to placebo in a
population of healthy adult males and females.
Phase:
Phase 1
Details
Lead Sponsor:
GlaxoSmithKline
Treatments:
Fluoroquinolones Moxifloxacin Norgestimate, ethinyl estradiol drug combination Rosiglitazone